

NCT02550080 Raw comparison:

Summary:
CHIA has 14 criteria while your personal folder has 16 criteria
Total found criteria: 14/14
Total not Found: 0/14
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Diagnosed with cutaneous vasculitis urticaria      │ Diagnosed with cutaneous vasculitis urticaria      │
│ psoriasis acne bullous skin diseases sterile       │ psoriasis acne bullous skin diseases sterile       │
│ pustulosis leprosy pneumocystis pneumonia and any  │ pustulosis leprosy pneumocystis pneumonia and any  │
│ other patients who need dapsone administration     │ other patients who need dapsone administration     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects are dapsone-naive                         │ Subjects are dapsone-naive                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ All subjects must have a clinical need for         │ All subjects must have a clinical need for         │
│ treatment with dapsone that precedes the decision  │ treatment with dapsone that precedes the decision  │
│ to participate in the study                        │ to participate in the study                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ All subjects are willing to complete the 6-weeks   │ All subjects are willing to complete the 6-weeks   │
│ period clinical trial                              │ period clinical trial                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ All subjects are written informed consent          │ All subjects are written informed consent          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has previously received Dapsone therapy            │ Has previously received Dapsone therapy            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The subject or any of their healthcare providers   │ The subject or any of their healthcare providers   │
│ is aware of the subjects HLA type                  │ is aware of the subjects HLA type                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has been diagnosed with Glucose-6-phosphate        │ Has been diagnosed with Glucose-6-phosphate        │
│ dehydrogenase deficiency or methemoglobin          │ dehydrogenase deficiency or methemoglobin          │
│ reductase deficiency                               │ reductase deficiency                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Satisfies any contraindications or restrictions to │ Satisfies any contraindications or restrictions to │
│ Dapsone therapy as listed in the product labels    │ Dapsone therapy as listed in the product labels    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current severe illness including heart liver and   │ Current severe illness including heart liver and   │
│ renal failure major organ allograft malignancy     │ renal failure major organ allograft malignancy     │
│ requiring parenteral chemotherapy that can not be  │ requiring parenteral chemotherapy that can not be  │
│ discontinued for the duration of the trial or any  │ discontinued for the duration of the trial or any  │
│ other conditions which in the opinion of the       │ other conditions which in the opinion of the       │
│ Investigator would make the patient unsuitable for │ Investigator would make the patient unsuitable for │
│ the study                                          │ the study                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any laboratory abnormality at Screening which in   │ Any laboratory abnormality at Screening which in   │
│ the opinion of the Investigator should preclude    │ the opinion of the Investigator should preclude    │
│ the subject's participation in the study [alanine  │ the subject's participation in the study \[alanine │
│ aminotransferase (ALT) glutamic oxaloacetic        │ aminotransferase (ALT) glutamic oxaloacetic        │
│ transaminase(ALT) et al)                           │ transaminase(ALT) et al)                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant women or women who are breastfeeding      │ Pregnant women or women who are breastfeeding      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is in the opinion of the Investigator      │ Subject is in the opinion of the Investigator      │
│ unable to complete the 6 week Observation period   │ unable to complete the 6 week Observation period   │
│ and the EPT assessments as required                │ and the EPT assessments as required                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A positive result for HLA-B*1301 in those subjects │ A positive result for HLA-B\*1301 in those         │
│ randomised to the genetic screening arm            │ subjects randomised to the genetic screening arm   │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 65 Years │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛